Rite Aid Corporation

OTCPK:RADC.Q Stock Report

Market Cap: US$2.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Rite Aid Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jeffrey Stein

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2.5yrs
Board average tenure5.4yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 16

Rite Aid Shareholders Are Wiped Out Under A Chapter 11 Bankruptcy Plan

Summary Rite Aid File for Ch.11 bankruptcy on October 15. Under the plan shareholders get no recovery and shares will be cancelled. There is a stalking horse bid of $575 million for Elixir. Secured noteholders get 100% of the new equity. McKesson is trying to terminate their supply contract with Rite Aid. Read the full article on Seeking Alpha
Seeking Alpha • Jul 10

Rite Aid May Be Forced Into Ch.11 Bankruptcy To Resolve Opioid Liabilities

Summary Rite Aid's stock is being downgraded from "Hold" to "Sell" due to the opioid lawsuit, ongoing financial losses, and ineffective management. Rite Aid reported a $(5.56) net loss per share for 1Q. Elixir will discontinue their Medicare Part D program for individuals starting next year. The stock is effectively trading at only about $0.08 after adjusting for the 1-20 reverse stock split a few years ago. Read the full article on Seeking Alpha
Seeking Alpha • Jun 27

Rite Aid Q1 Earnings Preview: Bears Remain In Control

Summary Bears remain resolute in their strong bet against Rite Aid. Weak outlook from Walgreens hurt RAD stock ahead of the Q1 2024 report. Debt leverage and cost run rate remain a concern. Read the full article on Seeking Alpha
Seeking Alpha • Jan 09

Rite Aid names interim CEO as Heyward Donigan departs

Healthcare industry expert Elizabeth Burr has been elected as interim CEO at U.S. drugstore chain Rite Aid (NYSE:RAD), effective immediately. Burr, a member of the company’s board, will succeed president and CEO Heyward Donigan, who has left the company. She has extensive experience in the health industry, having previously served as VP, Head of Health Ventures and Chief Innovation Officer at Humana. The firm has initiated a search to identify a permanent CEO and has retained a leading executive search firm. In addition, Rite Aid (RAD) reiterated its fiscal 2023 financial guidance for total revenues of $23.7B and $24B vs. $21.63B consensus, net loss between $584M and $551M, adjusted EBITDA between $410M and $440M and capital expenditures of ~$225M. RAD shares gained 2% in Monday's premarket session
Seeking Alpha • Dec 20

Rite Aid Q3 2023 Earnings Preview

Rite Aid (NYSE:RAD) is scheduled to announce Q3 earnings results on Wednesday, December 21st, before market open. The consensus EPS Estimate is -$0.31 and the consensus Revenue Estimate is $5.94B (-4.7% Y/Y). Over the last 2 years, RAD has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 1 upward revision and 1 downward.
Seeking Alpha • Nov 15

Rite Aid spikes 20% on above average volume

The beaten-down pharmacy retailer Rite Aid Corporation (NYSE:RAD) climbed ~20% Tuesday on above-average volume, rallying alongside a buoyant broader market. About 3.0M Rite Aid (RAD) shares have changed hands compared to the 65-day average volume of ~2.6M. However, with its stock continuing to trade ~48% below the year-ago level, Rite Aid (RAD) shares have yet to surpass the mid-September levels. About 18% of the company’s float represents short interest. The rally coincides with gains in the major indices after Walmart (WMT) topped Street forecasts with its Q3 2022 results, and data on producer prices indicated signs of moderating inflation. Wall Street has remained bearish on Rite Aid (RAD) stock, with an average rating of Strong Sell from analysts. However, the Seeking Alpha Author ratings identify RAD as a Hold alongside SA’s Quant System, which consistently beats the market.
Seeking Alpha • Oct 11

Rite Aid partners with Google Cloud on pharmacy insights, customer engagement

Rite Aid (NYSE:RAD) has brokered a partnership with Google Cloud (NASDAQ:GOOG) that will provide the drug store chain with improved insights and customer experiences, as well as access to the Anthos platform for application deployment. Anthos will provide Rite Aid's (RAD) pharmacies with cloud computing capabilities on-site. In addition, it will support a vaccine scheduling tool, customer messaging infrastructure, and digital engagement platform. Rite Aid (RAD) will also benefit from Google Cloud's (GOOG) Retail Search product that provides customers with precise search results when shopping on the company's website. Also, Rite Aid (RAD) will migrate its enterprise data to Google Cloud (GOOG) using BigQuery which will provide improved insights into its finances, supply chain inventory, and customer information, powering data-driven decisions for its business operations. Check out why Seeking Alpha contributor WYCO Researcher rates Rite Aid (RAD) a hold.

CEO

Jeffrey Stein (55 yo)

less than a year
Tenure

Mr. Jeffrey Scott Stein is Chief Executive Officer and Chief Restructuring Officer at Rite Aid Corporation since October 16, 2023 and its Director since August 2024. He serves as Chief restructuring office...

Leadership Team

NamePositionTenureCompensationOwnership
Matthew Schroeder
CFO & Executive VP5.5yrsUS$2.75m0.36%
$ 7.8k
Jeffrey Stein
CEO, Chief Restructuring Officer & Directorless than a yearno datano data
Steven Bixler
Chief Accounting Officer & Senior VP1.7yrsno data0.0065%
$ 141.5
Byron Purcell
Vice President of Investor Relations & Treasurerno datano datano data
Christin Bassett
Acting General Counsel & Corporate Secretaryless than a yearno datano data
Joy Seusing
Senior VP & Chief Communications Officerno datano datano data
Jeanniey Walden
Senior VP & CMO1.5yrsno datano data
Jessica Kazmaier
Executive VP5.5yrsno data0.16%
$ 3.6k
Karen Staniforth
Senior VP of Clinical Pharmacy Services & Chief Pharmacy Officer2.5yrsno datano data
Angele Robinson-Gaylord
Senior Vice President of Store Development3.9yrsno datano data
Christopher DuPaul
Executive Vice President2.7yrsno data0.063%
$ 1.4k
2.5yrs
Average Tenure
54yo
Average Age

Experienced Management: RADC.Q's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jeffrey Stein
CEO, Chief Restructuring Officer & Directorless than a yearno datano data
Robert Knowling
Independent Director5.9yrsUS$264.55k0%
$ 0
Arun Nayar
Independent Director5.9yrsUS$270.00k0.000050%
$ 1.1
Bruce Bodaken
Independent Chairman of the Board11.3yrsUS$425.00k0.012%
$ 258.6
Elizabeth Burr
Director5.4yrsUS$858.46k0%
$ 0
Carrie Teffner
Directorless than a yearno datano data
Paul Keglevic
Directorless than a yearno datano data
Bari Harlam
Independent Director4yrsUS$272.63k0%
$ 0
Katherine Quinn
Independent Director5.4yrsUS$283.75k0%
$ 0
5.4yrs
Average Tenure
62yo
Average Age

Experienced Board: RADC.Q's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/03 03:44
End of Day Share Price 2024/09/03 00:00
Earnings2023/09/02
Annual Earnings2023/03/04

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rite Aid Corporation is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Steven ValiquetteBofA Global Research
William FrohnhoeferBTIG
George HillDeutsche Bank